UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Upf3b-mutant mouse model with behavioral and neurogenesis defects

Molecular psychiatry, 2018-08, Vol.23 (8), p.1773-1786

2018

Volltextzugriff (PDF)

Sixteen years of social and ecological dynamics reveal challenges and opportunities for adaptive management in sustaining the commons

Proceedings of the National Academy of Sciences - PNAS, 2019-12, Vol.116 (52), p.26474-26483

2019

Volltextzugriff (PDF)

Adipose tissue estimation of foraging and nesting green turtles Chelonia mydas using bioelectrical impedance analysis

Endangered species research, 2023-06, Vol.51, p.127-142

2023

Volltextzugriff (PDF)

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

Expert opinion on pharmacotherapy, 2017-05, Vol.18 (7), p.701-716

2017

Volltextzugriff (PDF)

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii541-viii542

2018

Volltextzugriff (PDF)

485P LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers

Annals of oncology, 2023-11, Vol.34, p.S1651

2023

Volltextzugriff (PDF)

DEVELOPMENT OF HORTICULTURAL THERAPY IN HONG KONG

Acta horticulturae, 2012 (954), p.169-174

2012

Volltextzugriff (PDF)

EP01.06-003 Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S189

2022

Volltextzugriff (PDF)

OA16.04 Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S81-S82

2023

Volltextzugriff (PDF)

EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S655-S656

2023

Volltextzugriff (PDF)

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.S59-S59

2024

Volltextzugriff (PDF)

P10.08 Comparing Lung Cancer in Never Smokers and Ever Smokers in Asian or Asian American Patients Treated at a Tertiary Urban Public Hospital in New York

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1001-S1002

2021

Volltextzugriff (PDF)

EP01.06-008 Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S191-S192

2022

Volltextzugriff (PDF)

LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

Annals of oncology, 2023-10, Vol.34, p.S1313-S1314

2023

Volltextzugriff (PDF)

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

International journal of radiation oncology, biology, physics, 2022-11, Vol.114 (3), p.S31

2022

Volltextzugriff (PDF)

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4

Oncogene, 2006-09, Vol.25 (41), p.5664-5672

2006

Volltextzugriff (PDF)

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

Annals of oncology, 2022-09, Vol.33, p.S1019-S1020

2022

Volltextzugriff (PDF)

36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

Annals of oncology, 2021-03, Vol.32, p.S15-S15

2021

Volltextzugriff (PDF)

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1671-S1672

2023

Volltextzugriff (PDF)

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-10, Vol.34, p.S755-S756

2023

Volltextzugriff (PDF)

Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial

Lancet neurology, 2010-05, Vol.9 (5), p.489-497

2010

Volltextzugriff (PDF)

EP08.02-045 Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S418

2022

Volltextzugriff (PDF)

EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S406

2022

Volltextzugriff (PDF)

P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S614-S614

2021

Volltextzugriff (PDF)

Virtual multidisciplinary stroke care clinic for community-dwelling stroke survivors: a randomised controlled trial (abridged secondary publication)

Hong Kong medical journal = Xianggang yi xue za zhi, 2024-06, Vol.30 Suppl 3 (3), p.32

2024

Volltextzugriff (PDF)

1 – 25 von 751

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(606)
Mit Volltextzugriff
(611)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A Upf3b-mutant mouse model with behavioral and neurogenesis defects

Sixteen years of social and ecological dynamics reveal challenges and opportunities for adaptive management in sustaining the commons

Adipose tissue estimation of foraging and nesting green turtles Chelonia mydas using bioelectrical impedance analysis

Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer

Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

485P LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers

DEVELOPMENT OF HORTICULTURAL THERAPY IN HONG KONG

EP01.06-003 Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population

OA16.04 Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS)

EP12.01-38 Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype

The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes

P10.08 Comparing Lung Cancer in Never Smokers and Ever Smokers in Asian or Asian American Patients Treated at a Tertiary Urban Public Hospital in New York

EP01.06-008 Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis

LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4

1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients

36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial

EP08.02-045 Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer

EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

P76.62 RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

Virtual multidisciplinary stroke care clinic for community-dwelling stroke survivors: a randomised controlled trial (abridged secondary publication)

Suchergebnisse filtern